Bispecific agents target endogenous murine T cells against human tumor xenografts

International Journal of Cancer

Volumn 83, Issue 1, 1999, Pages 141-149

  Rund, Laurie A ^a   Cho, Bryan K ^a   Manning, Thomas C ^a   Holler, Phillip D ^a   Roy, Edward J ^a   Kranz, David M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL INFILTRATION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FLOW CYTOMETRY; GENES, RAG-1; GENES, T-CELL RECEPTOR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032845322     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990924)83:1<141::AID-IJC24>3.0.CO;2-0     Document Type: Article

References (29)

1. ALBERTS, D.S., LIEU, P.Y., HANNIGEN, E.V., O'TOOLE, R., WILLIAMS, S.D., YOUNG, J.A., FRANKLIN, E.W., CLARKE-PEARSON, D.L., MALVIYA, V.K., DUBESHTER, B., ADELSON, M.D. and HOSKINS, W.J., Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage-III ovarian cancer. New Engl. J. Med., 335, 1950-1955 (1996).
2. BAKACS, T., LEE, J., MORENO, M.B., ZACHARCHUK, C.M., COLE, M.S., TSO, J.Y., PAIK, C.H., WARD, J.M. and SEGAL, D.M., A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma. Int. Immunol., 7, 947-955 (1995).
3. BLUESTONE, J.A., BRUCE, D.S. and NEWELL, K.A., Activation of T cells in vivo using anti-CD3 and staphylococcal enterotoxins. Int. J. Cancer, Suppl., 7, 39-41 (1992).
4. BOLHUIS, R.L.H., LAMERS, C.H.J., GOEY, H.S., EGGERMONT, A.M.M., TRIMBOS, J.B., STOTER, G., LANZAVECCHIA, A., DI RE, E., MIOTTI, S., RASPAGLIESI, F., RIVOLTINI, L. and COLNAGHI, M.I., Adoptive immuno-therapy of ovarium carcinoma with Bs-MAb targeted lymphocytes. A multicenter study. Int. J. Cancer, Suppl., 7, 78-81 (1992).
5. BRAAKMAN, E., GOEDEGEBUURE, P.S., VREUGDENHIL, R.J., SEGAL, D.M., SHAW, S. and BOLHUIS, R.L., ICAM-melanoma cells are relatively resistant to CD3-mediated T-cell lysis. Int. J. Cancer, 46, 475-480 (1990).
6. CANEVARI, S. and 17 OTHERS, Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes re-targeted by a bispecific monoclonal antibody. J. nat. Cancer Inst., 87, 1463-1469 (1995).
7. CHO, B.K., ROY, E.J., PATRICK, T.A. and KRANZ D.M., Efficient CTL lysis of folate-receptor-positive tumor cells mediated by single-chain Fv/folate conjugates. Bioconj. Chem., 8, 338-346 (1997).
8. CHO, B.K., SCHODIN, B.A. and KRANZ, D.M., Characterization of a single-chain antibody to the β-chain of the T-cell receptor. J. biol. Chem., 270, 25819-25826 (1995).
9. FANGER, M.W., MORGANELLI, P.M. and GUYRE, P.M., Use of bispecific antibodies in the therapy of tumors. Cancer Treat. Res., 68, 181-194 (1993).
10. GOEDEGEBUURE, P.S., BRAAKMAN, E., SEGAL, D.M., VREUGDENHIL, R.J. and BOLHUIS, R.L., Lymphocyte/leukocyte-function-associated antigen 1 interacting with target-cell intercellular adhesion molecule 1 co-activates cytolysis triggered via CD16 or the receptor involved in major-histocompatibility-antigen-unrestricted lysis. Int. Immunol., 2, 1213-1220 (1990).
11. KRANZ, D.M., PATRICK, T.A., BRIGLE, K.E., SPINELLA, M.J. and ROY, E.J., Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. nat. Acad. Sci. (Wash.), 92, 9057-9061 (1995).
12. KRANZ, D.M., TONEGAWA, S. and EISEN, H.N., Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc. nat. Acad. Sci. (Wash.), 81, 7922-7926 (1984).
13. LAMERS, C.H., BOLHUIS, R.L., WARNAAR, S.O., STOTER, G. and GRATAMA, J.W., Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. Int. J. Cancer, 73, 211-219 (1997).
14. LEAMON, C.P., PASTAN, I. and Low, P.S., Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J. biol. Chem., 268, 24847-24854 (1993).
15. LUITEN, R.M., WARNAAR, S.O., SANBORN, D., LAMERS, C.H., BOLHUIS, R.L., LITVINOV, S.V., ZURAWSKI, V.R., JR. and CONEY, L.R., Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. J. Immunother., 20, 496-504 (1997).
16. -/- mice. J. Immunol., 159, 4665-4675 (1997).
17. MATHIAS, C.J., WANG, S., LEE, R.J., WATERS, D.J., Low, P.S. and GREEN, M.A., Tumor-selective radiopharmaceutical targeting via receptor-mediate endocytosis of gallium-67-deferoxamine folate. J. nucl. Med., 37, 1003-1008 (1996).
18. MAZZONI, A., MEZZANZANICA, D., JUNG, G.R., WOLF, H., COLNAGHI, M.I. and CANEVARI, S., CD3-CD28 co-stimulation as a means to avoiding T-cell pre-activation in bispecific monoclonal-antibody-based treatment of ovarian carcinoma. Cancer Res., 56, 5443-5449 (1996).
19. MEZZANZANICA, D., GARRIDO, M.A., NEBLOCK, D.S., DADDONA, P.E., ANDREW, S.M., ZURAWSKI, V.R., JR., SEGAL, D.M. and WUNDERLICH, J.R., Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res., 51, 5716-5721 (1991).
20. MOMBAERTS, P., IACOMINI, J., JOHNSON, R.S., HERRUP, K., TONEGAWA, S. and PAPAIOANNOU, V.E., RAG-1-deficient mice have no mature B and T lymphocytes. Cell, 68, 869-877 (1992).
21. PATRICK, T.A., KRANZ, D.M., ZACHARY, J.F. and ROY, E.J., Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors. Int. J. Cancer, 78, 470-479 (1998).
22. RENNER, C. and PFREUNDSCHUH, M., Tumor therapy by immune recruitment with bispecific antibodies, Immunol. Rev., 145, 179-209 (1995).
23. ROSS, J.F., CHAUDHURI, P.K. and RATNAM, M., Differential regulation of folate-receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer, 73, 2432-2443 (1994).
24. ROY, E.J., CHO, B.K., RUND, L.A., PATRICK, T.A. and KRANZ, D.M., Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate. Int. J. Cancer, 76, 761-766 (1998).
25. SHA, W.C., NELSON, C.A., NEWBERRY, R.D., KRANZ, D.M., RUSSELL, J.H. and LOH, D.Y., Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature (Lond.), 335, 271-274 (1988).
26. + cytotoxic T lymphocytes in association with a class-I-MHC protein. Cell, 69, 989-998 (1992).
27. UDAKA, K., WIESMULLER, K., KIENLE, S., JUNG, G. and WALDEN, P., Self-MHC-restricted peptides recognized by an alloreactive T-lymphocyte clone. J. Immunol., 157, 670-678 (1996).
28. WEIJTENS, M.E., WILLEMSEN, R.A., VAN KRIMPEN, B.A. and BOLHUIS, R.L., Chimeric scFv/gamma-receptor-mediated T-cell lysis of tumor cells is co-regulated by adhesion and accessory molecules. Int. J. Cancer, 77, 181-187 (1998).
29. ZHU, H., MELDER, R.J., BAXTER, L.T. and JAIN, R.K., Physiologically based kinetic model of effector-cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res., 56, 3771-3781 (1996).